Sarepta Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $801.3M | $1.10B | $428.4M | $966.8M | $2.12B | $1.50B | $835.1M | $370.8M |
| Accounts Receivable | $398.2M | $602.0M | $400.3M | $214.6M | $153.0M | $101.3M | $90.9M | $49.0M |
| Inventory | $914.7M | $750.0M | $322.9M | $204.0M | $186.2M | $232.0M | $171.4M | $125.4M |
| Total Current Assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B |
| Property, Plant & Equipment | $345.1M | $340.3M | $227.2M | $180.0M | $191.2M | $190.4M | $129.6M | $97.0M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $28.9M | $26.9M | $29.6M | $7.6M | $14.2M | $13.6M | $12.5M | $11.6M |
| Total Assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B |
| Liabilities | ||||||||
| Accounts Payable | $280.8M | $214.4M | $164.9M | $95.9M | $76.7M | $111.1M | $68.1M | $33.8M |
| Total Current Liabilities | $1.10B | $731.7M | $653.7M | $619.6M | $452.7M | $416.0M | $264.8M | $173.7M |
| Long-Term Debt | $829.0M | $1.14B | $1.24B | $1.54B | $563.7M | — | — | $420.6M |
| Total Liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $609.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-4.88B | $-4.21B | $-4.45B | $-3.91B | $-3.21B | $-2.85B | $-2.29B | $-1.58B |
| Total Stockholders' Equity | $1.14B | $1.53B | $859.3M | $385.0M | $928.0M | $761.8M | $818.2M | $1.03B |